Bhalchandra Mirlekar
YOU?
Author Swipe
View article: Supplementary Tables from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer
Supplementary Tables from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer Open
Supplementary Tables 1-3
View article: Supplementary Tables from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer
Supplementary Tables from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer Open
Supplementary Tables 1-3
View article: Supplementary Figures from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer
Supplementary Figures from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer Open
Supplementary Figures 1-14
View article: Supplementary Figures from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer
Supplementary Figures from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer Open
Supplementary Figures 1-14
View article: Data from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer
Data from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8+ T cells and resistance to immunotherapeutic interventions. Cancer-associated mechanisms that elicit CD8+
View article: Data from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer
Data from B cell–Derived IL35 Drives STAT3-Dependent CD8<sup>+</sup> T-cell Exclusion in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8+ T cells and resistance to immunotherapeutic interventions. Cancer-associated mechanisms that elicit CD8+
View article: Data from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Data from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
Although successes in cancer immunotherapy have generated considerable excitement, this form of treatment has been largely ineffective in patients with pancreatic ductal adenocarcinoma (PDA). Mechanisms that contribute to the poor antitumo…
View article: Supplementary Figure 4 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 4 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This Figure demonstrates examples of p35+ and Ebi3+ B cells and T cells in primary human PDAC tumors, as well as gives examples of CD8 T cell infltrated versus depleted regions in tumors
View article: Supplementary Figure 3 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 3 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This figure demonstrates that deletion of IL12 subunit p40 does not activate anti-tumor immune response
View article: Supplementary Figure 5 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 5 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This Figure documents successful depletion of CD8 T cells from mice, and shows results of tumor growth studies on mice with IL35 deficiency and treated with anti-PD1
View article: Supplementary Figure 4 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 4 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This Figure demonstrates examples of p35+ and Ebi3+ B cells and T cells in primary human PDAC tumors, as well as gives examples of CD8 T cell infltrated versus depleted regions in tumors
View article: Supplementary Figure 1 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 1 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This figure demonstrates that host deficiency for IL-35 does not affect myeloid cell frequency
View article: Supplementary Figure 3 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 3 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This figure demonstrates that deletion of IL12 subunit p40 does not activate anti-tumor immune response
View article: Data from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Data from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
Although successes in cancer immunotherapy have generated considerable excitement, this form of treatment has been largely ineffective in patients with pancreatic ductal adenocarcinoma (PDA). Mechanisms that contribute to the poor antitumo…
View article: Supplementary Figure 2 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 2 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This figure demonstrates that infiltrating immune cells contain low amounts of cytokines IL12 and IL27
View article: Supplementary Figure 2 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 2 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This figure demonstrates that infiltrating immune cells contain low amounts of cytokines IL12 and IL27
View article: Supplementary Figure 1 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 1 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This figure demonstrates that host deficiency for IL-35 does not affect myeloid cell frequency
View article: Supplementary Figure 5 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Supplementary Figure 5 from IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer Open
This Figure documents successful depletion of CD8 T cells from mice, and shows results of tumor growth studies on mice with IL35 deficiency and treated with anti-PD1
View article: STING-induced regulatory B cells compromise NK function in cancer immunity
STING-induced regulatory B cells compromise NK function in cancer immunity Open
View article: Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity
Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity Open
Plasma cell responses are associated with anti-tumor immunity and favorable response to immunotherapy. B cells can amplify anti-tumor immune responses through antibody production; yet B cells in patients and tumor-bearing mice often fail t…
View article: B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer
B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer Open
B cells can act as potent suppressors of anti-tumor T cell immunity, presenting a mechanism of resistance to immunotherapy. In pancreatic ductal adenocarcinoma, B cells can display a T cell-suppressive or regulatory phenotype centered on t…
View article: Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy Open
Cytokines play a critical role in regulating host immune response toward cancer and determining the overall fate of tumorigenesis. The tumor microenvironment is dominated mainly by immune-suppressive cytokines that control effector antitum…
View article: STING-induced regulatory B cells compromise NK function in cancer immunity
STING-induced regulatory B cells compromise NK function in cancer immunity Open
An immunosuppressive tumour microenvironment is a major obstacle in the control of pancreatic and other solid cancers1–3. Agonists of the stimulator of interferon genes (STING) protein trigger inflammatory innate immune responses to potent…
View article: Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy Open
Cytokines play a critical role in regulating host immune response toward cancer and determining the overall fate of tumorigenesis. The tumor microenvironment is dominated mainly by immune-suppressive cytokines that control effector antitum…
View article: B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer
B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer Open
B cells can act as potent suppressors of anti-tumor T cell immunity, presenting a mechanism of resistance to immunotherapy. In pancreatic ductal adenocarcinoma, B cells can display a T cell-suppressive or regulatory phenotype centered on t…
View article: Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity
Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity Open
Plasma cell responses are associated with anti-tumor immunity and favorable response to immunotherapy. B cells can amplify anti-tumor immune responses through antibody production; yet B cells in patients and tumor-bearing mice often fail t…
View article: Impact of IL-23 in prostate cancer
Impact of IL-23 in prostate cancer Open
Cytokines play an essential role in governing the overall immune response toward cancer. Recently, the role of IL-12 family cytokines in dictating immune response toward cancer has been well appreciated.1 IL-23 is one of such heterodimeric…
View article: IMMU-48. IMMUNOMODULATION WITH RESIQUIMOD REPOLARIZES THE IMMUNE MICROENVIRONMENT TO INHIBIT MEDULLOBLASTOMA PROGRESSION
IMMU-48. IMMUNOMODULATION WITH RESIQUIMOD REPOLARIZES THE IMMUNE MICROENVIRONMENT TO INHIBIT MEDULLOBLASTOMA PROGRESSION Open
BACKGROUND New, non-cytotoxic treatments may improve outcomes for medulloblastoma, the most common malignant pediatric brain tumor. Sonic hedgehog (SHH) subgroup medulloblastoma, which includes subtypes with poor prognosis, can be modeled …
View article: IL-12 Family Cytokines in Cancer and Immunotherapy
IL-12 Family Cytokines in Cancer and Immunotherapy Open
The IL-12 family cytokines are a group of unique heterodimeric cytokines that include IL-12, IL-23, IL-27, IL-35 and, most recently, IL-39. Recent studies have solidified the importance of IL-12 cytokines in shaping innate and adaptive imm…
View article: Regulatory B cells in cancer
Regulatory B cells in cancer Open
Tumorigenesis proceeds through discrete steps where acquisition of genetic lesions and changes in the surrounding microenvironment combine to drive unrestricted neoplastic proliferation and metastasis. The ability of tumor‐infiltrating imm…